Genomic Vision Has Presented the First Results of Its HPV Detection Test at the HPV 2014 Conference in Seattle

Regulatory News :

Genomic Vision (Paris:GV) (FR0011799907 – GV / PEA-PME eligible), a molecular diagnosis company that specializes in the development of diagnostic tests for genetic diseases and cancers using the DNA molecular combing process, today announces that the first results of its development program for a test to detect the Human Papilloma Virus (HPV) in cervical cancer were presented in the form of a poster at the 29^th edition of the HPV conference (International Papillomavirus Conference and Clinical & Public Health Workshops), which was held in Seattle (USA) from August 21 to 25, 2014.

Cervical cancer resulting from an infection of the cervix by HPV is the 2^nd most common form of cancer among women, just behind breast cancer. Each year, almost 500,000 new cases and between 250,000 and 300,000 deaths are recorded worldwide. Its development can be halted with a very favorable prognosis (5-year survival rate of 90%) when the lesions that precede it are detected sufficiently early. So far, the screening, diagnosis and survival of patients have been essentially based on cervical smears, colposcopies and biopsies.

The integration of HPV viral DNA in the genome of the infected cell being a major stage in the progression of tumors, the test currently being developed by Genomic Vision aims to directly detect not only the presence of viral DNA, but also its integration in the infected cell genome. This HPV integration cannot be directly detected by existing tests.

The preliminary results have shown that molecular combing technology allows the direct and high-resolution visualization of the integration of high-risk HPV genomes (HPV16 and HPV18 as unique or tandem array) in the cervical-cancer-derived cell lines and in the cervical smears of patients with lesions at various stages of the disease’s evolution.

These results also highlight the possibility of exploring the integration of high-risk HPV genomes at individual locus level, such as that of the c-Myc oncogene involved in controlling cellular proliferation.

Aaron Bensimon, Genomic Vision’s co-founder and Chairman, says: "These preliminary results of our HPV test give us real confidence regarding the pursuance of its clinical validation. Indeed, they show that molecular combing can enhance screening and help identify the HPV infections with the highest risk and hence enable patients to be steered towards the most suitable treatment, therefore avoiding the need for unnecessary, invasive and expensive colposcopies.”

???

ABOUT GENOMIC VISION
A spinoff of the Institut Pasteur, Genomic Vision is a molecular diagnostics company specialized in developing diagnostic tests for genetic diseases and cancers. Using "molecular combing”, an innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. Having benefited from the financial support of the Institut Pasteur, SGAM AI, Vesalius Biocapital and Quest Diagnostics, the Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France.

ABOUT MOLECULAR COMBING
DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if "combed”, and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient’s genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to www.genomicvision.com

DISCLAIMER

This press release contains certain forward-looking statements concerning Genomic Vision and its business.
Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.